<unk>  (MGRS) are a group of kidney disorders that present with kidney damage due to nephrotoxic<unk>  immunoglobulins (M proteins) secreted by clonal plasma cells or B cells. By definition, people with MGRS do not meet criteria for multiple myeloma or other hematologic malignancies. The term MGRS was introduced in 2012 by the International Kidney and<unk>  Gammopathy Research Group (IKMG). MGRS is associated with<unk>  gammopathy of undetermined<unk>  (MGUS). People with MGUS have a<unk>  gammopathy (presence of<unk>  immunoglobulins) but does not meet the criteria for the clonal burden nor the presence of end organ damage seen in hematologic malignancies. In a population based study based on the NHANES III health survey; 6% of patients with MGUS were subsequently classified as having MGRS. The prevalence and incidence of MGRS in the general population or in specific populations is not known but it is more prevalent in those over the age of 50 as there is a<unk>  protein (M-protein) present in 3% of those 50 and years older and 5% of those 70 years and older (the presence of MGUS), placing those 50 and older at increased risk of MGRS. MGRS disorders generally do not respond well to immunosuppressive treatment. MGRS disorders also have a greater than 90% rate of recurrence if the<unk>  gammopathy is not eliminated either before or immediately after a renal transplant. People with MGRS are at risk of progression to the corresponding hematologic malignancy.
Monoclonal gammopathy of renal significance
Monoclonal gammopathy of undetermined significance
Familial renal amyloidosis
AL amyloidosis
Secondary systemic amyloidosis
Myeloma cast nephropathy
Haemodialysis-associated amyloidosis
AA amyloidosis